ArticleProbiotics and antimicrobial proteins2025
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping Review.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.Alimentary pharmacology & therapeutics · 2026Review
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- The Gut-Heart Axis: A Microbiome-Centered Perspective on Heart Failure.International journal of molecular sciences · 2026Review
- Paradigm Shift of Microbiota-gut-brain Axis During Aging: Potential Role of Probiotics to Improve Cognitive Decline.Probiotics and antimicrobial proteins · 2026Review
- Cardiometabolic Effects of Traditional South Asian Diets and the Growing Burden of Metabolic Syndrome.Archives of internal medicine research · 2026Article
- The Gut Microbiome in Early Ontogeny: Implications for Brain and Immune System Development.Journal of developmental biology · 2026Review
- Review
- The Wine Ecosystem as a Reservoir for Potential Probiotics: A Comparative In Vitro Evaluation ofFoods (Basel, Switzerland) · 2026Article
- Review
- Managing Gut Dysbiosis: Clinical Evidence and Perspectives onMicroorganisms · 2026Review
- Exploring the Gut Microbiome in Combat Sports: A Systematic Scoping Review.Sports (Basel, Switzerland) · 2026Review
- The role of the gut microbiome in antibiotic-driven antimicrobial resistance.Frontiers in microbiology · 2026Review
- Fecal microbiota transplantation for intractable diarrhea due to severe dysbiosis and cytomegalovirus enteritis: a case report.Frontiers in nutrition · 2026Article
- Combined Prebiotic Extract of Mung Bean, Red Bean, and Fennel Improves Intestinal Barrier Integrity in HT-29 Cells and DSS-Induced Colitis via Gut Microbiota Alteration.Current issues in molecular biology · 2025Article
- Correlation Between Dysbiosis and Atrial Fibrillation: What's New?International journal of molecular sciences · 2025Review
- Gut-Brain Axis and Bile Acid Signaling: Linking Microbial Metabolism to Brain Function and Metabolic Regulation.International journal of molecular sciences · 2025Review
- Intestinal and esophageal microbiota in esophageal cancer development and treatment.Gut microbes · 2025Review
- The association of ZJU index with bowel health in US participants: a cross-sectional study.European journal of medical research · 2025Article
- Bioactive Peptides from Quinoa (Nutrients · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysbiosis is a clinical condition marked by altered gut microbiota resulting from external and internal host factors. It is strongly associated with gastrointestinal and extraintestinal alterations, so its symptomatology is broad and nonspecific. To date, gaps remain that limit professionals from making a timely diagnosis and prescribing the appropriate treatment. We aim to synthesize existing literature regarding clinical parameters for the early detection of patients with intestinal dysbiosis and the clinical events in which the use of probiotics as adjuvant therapy is most frequently reported. A scoping review of the literature was conducted in PubMed, Embase, Cochrane, and BVS (Biblioteca Virtual en Salud in Spanish) databases for articles published in the last 5 years. Primary studies and literature reviews related to clinical presentation, dysbiosis screening, and probiotics as adjuvant therapy for adult and pediatric patients were included. Twenty-three articles were retrieved in which the most frequently reported symptoms were abdominal distension, abdominal pain, and diarrhea. Chronic and metabolic diseases where the conditions most strongly associated with dysbiosis. Depending on symptomatology and etiology, dysbiosis is often treated with probiotics. Dysbiosis, often linked to diarrhea, should be considered with other symptoms like abdominal distension and pain, along with predisposing conditions and patient risk factors. Probiotics are commonly used as co-adjuvant treatments for antibiotic-associated diarrhea, irritable bowel syndrome, and childhood allergic diseases. The most commonly used probiotics were Weizmannia coagulans (formerly B. coagulans), Alkalihalobacillus clausii (formerly Bacillus clausii), Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Saccharomyces boulardii.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.